T. Rowe Price announced the launch of three new actively managed equity exchange traded funds, T. Rowe Price Biotech ETF, T. Rowe Price Small-Cap ETF and T. Rowe Price Mid-Cap Equity Research ETF, all of which began trading on the NASDAQ today. The three funds bring the firm's total ETF lineup to 38 funds, after eight new active exchange traded offerings were added this year. The Biotech ETF, ticker TDNA, is managed by John Hall and is expected to hold approximately 60-120 companies with an expense ratio of 0.55%. The Small-Cap ETF, ticker TSEE, is managed by Alex Roik, typically holds 200 or more stocks and carries an expense ratio of 0.59%. The Mid-Cap Equity Research ETF, ticker TMID, expands the firm's Structured Research Strategies lineup, is managed by Paige Davis Jr., Amanda Ludwitzke and Thomas Watson, typically holds more than 300 stocks and has an expense ratio of 0.47%. Tim Coyne, Global Head of ETFs, said the funds broaden investors' access to distinct areas of the market while combining the firm's research capabilities with the fully transparent ETF structure.
T. Rowe Price Group IncT. Rowe Price launched three new actively managed ETFs, expanding its ETF lineup to 38 funds and growing its product/fee base.
